Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers

NCT02388009 is registered in ClinicalTrials.gov with LimmaTech Biologics AG as lead sponsor.

NCT NCT02388009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02388009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers
Lead sponsor
LimmaTech Biologics AG
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2015
Completion date
September 30, 2015
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

shigellosis